Trump unveils plan to slash drug costs tied to what’s paid abroad

Photo of author

By admin

Prices for drugs administered by doctors will be linked to a “most-favored-nation price” drawn from the lowest price among members of the Organization for Economic Cooperation and Development that have a similar per-capita gross domestic product, the executive order states.

The order directs federal health officials to carry out demonstration projects for Medicare Part B, a move that would bypass the monthslong process of rulemaking and could start the price cuts before Election Day.

It also would develop a similar rule for Medicare Part D, or those drugs that patients pick up at the pharmacy counter. The Part D rule would apply to drugs without much competition for which seniors pay prices higher than those in comparable OECD countries.

The White House also considered distributing $100 coupons to Medicare patients, a move that could have been similarly be fast-tracked to deliver one-time savings to roughly 25 million people before the election, one lobbyist said. But White House had sparred with Centers for Medicare and Medicaid over the feasibility of the plan.

The pharmaceutical industry and many conservative groups vehemently oppose the most favored nations plan over the way it would effectively import foreign governments’ price controls. An alternative proposed by drug lobby PhRMA last month would lower costs more modestly in Medicare Part B and Part D by giving a “market based discount” on the often pricey physician-administered drugs and installing a cap on patient cost-sharing for pharmacy counter medicines.

Trump in July gave the drug industry a one-month deadline to come up with an alternative plan. But pharmaceutical companies refused to meet with the president and the deadline passed.

An industry alternative delivered to the White House in late August would have saved the government and seniors significantly less money but could also have been implemented before the election and help Trump deliver on a signature promise in his 2016 campaign.

But talks between PhRMA and the White House broke down last week, according to two lobbyists.

Susannah Luthi and Dan Diamond contributed to this report.

Source link

Leave a Comment